| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 4,375 | 4,375 |
| Net decrease in cash and cash equivalents | -9,118 | -5,140 |
| Cash and cash equivalents at beginning of period | 13,985 | - |
| Cash and cash equivalents at end of period | 4,867 | - |
FibroBiologics, Inc. (FBLG)
FibroBiologics, Inc. (FBLG)